1491. The Risk of Febrile Seizures Following Influenza and 13-Valent Pneumococcal Conjugate Vaccines  
Session: Poster Abstract Session: Pneumococcal Immunization and Epidemiology-North America
Friday, October 6, 2017
Room: Poster Hall CD
Posters
  • Baker_ID Week Poster.pdf (440.8 kB)
  • Background:

    Evidence on the risk of febrile seizures (FS) after vaccination with inactivated influenza vaccine (IIV) and 13-valent pneumococcal conjugate vaccine (PCV13) is mixed. Among children 6-23 months, we examined the risk of FS following IIV and PCV13 during the 2013-14 and 2014-15 influenza seasons, for which vaccine virus strains were the same.

    Methods:

    We used claims data from 4 large national insurers in the FDA-sponsored Sentinel Initiative, which was developed to monitor the safety of FDA-regulated medical products.

    With a self-controlled risk interval design, the risk of FS in 0-1 days following IIV and following PCV13 was compared to a comparison interval (14-20 days), adjusting for confounding by age, calendar time, and concomitant vaccination with the other vaccine. In exploratory analyses, we assessed whether the effect of IIV is modified by concomitant administration of PCV13.

    Results:

    During the study period, 355,486 children received IIV and 581,868 received PCV13. We observed an incidence rate ratio (IRR) of 1.12 (95% CI 0.80, 1.56) for the risk of FS following IIV after adjustment for age, calendar time and concomitant PCV13. PCV13 was associated with an increased risk of FS (IRR adjusted for age, calendar time and concomitant IIV, 1.80, 95% CI 1.29, 2.52). The attributable risk for PCV13 ranged from 0.33 to 5.16 per 100,000 doses.

    The age and calendar-time adjusted IRR comparing exposed time to unexposed time was greater for concomitant IIV and PCV13 (IRR 2.80, 95% CI 1.63, 4.83), as compared to that for PCV13 without concomitant IIV (IRR 1.54, 95% CI 1.04, 2.28). However, the formal test assessing for interaction between IIV and PCV13 was not statistically significant.

    Conclusion:

    We found an elevated risk of FS after PCV13 vaccine but not after IIV, when adjusting for concomitant administration of the other vaccine. We found some evidence to suggest that concomitant administration of IIV with PCV13 might interact to increase the risk beyond the independent effects of PCV13, but the study was not powered to assess this interaction. The risk of seizures associated with PCV13 is low compared to a child’s lifetime risk of FS. Findings should be interpreted in the context of the importance of preventing influenza and pneumococcal infections in young children.

    Meghan Baker, MD, ScD1,2, Christopher Jankosky, MD, MPH3, Katherine Yih, PhD, MPH1, Susan Gruber, PhD1, Lingling Li, PhD4, Noelle Cocoros, DSc, MPH1, Hana Lipowicz, MPH1, Claudia Coronel-Moreno, MPH1, Sandra Feibelmann, MPH1, Nancy Lin, ScD5, Cheryl McMahill-Walraven, PhD, MSW6, David Menschik, MD, MPH3, Mano Selvan, PhD7, Nandini Selvam, PhD, MPH8, Rong Chen Tilney, MS1, Lauren Zichittella, MS1, Grace Lee, MD, MPH, FPIDS1,9 and Alison Tse Kawai, ScD, SM1, (1)Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, (2)Brigham and Women's Hospital, Boston, MA, (3)FDA Center for Biologics Evaluation and Research, Silver Spring, MD, (4)Sanofi Genzyme, Cambridge, MA, (5)Optum Epidemiology, Boston, MA, (6)Aetna, Blue Bell, PA, (7)Comprehensive Health Insights, Sugar Land, TX, (8)QuintilesIMS, Fairfax, VA, (9)Division of Infectious Diseases, Boston Children's Hospital, Boston, MA

    Disclosures:

    M. Baker, None

    C. Jankosky, None

    K. Yih, None

    S. Gruber, None

    L. Li, Sanofi Pasteur: The author is currently employed by Sanofi Genzyme, which shares the same parent company as Sanofi Pasteur, the manufacturer of the Flu vaccine. However, the work was done while this author was still employed by Harvard Pilgrim Health Care Institute. , No financial benefit received

    N. Cocoros, None

    H. Lipowicz, None

    C. Coronel-Moreno, None

    S. Feibelmann, None

    N. Lin, None

    C. McMahill-Walraven, None

    D. Menschik, None

    M. Selvan, None

    N. Selvam, None

    R. C. Tilney, None

    L. Zichittella, None

    G. Lee, None

    A. T. Kawai, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.